{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T23:56:24Z","timestamp":1789516584533,"version":"build-2803163510"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,10,12]],"date-time":"2017-10-12T00:00:00Z","timestamp":1507766400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1007\/s40256-017-0251-2","type":"journal-article","created":{"date-parts":[[2017,10,12]],"date-time":"2017-10-12T05:26:09Z","timestamp":1507785969000},"page":"75-82","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Does Coenzyme Q10 Supplementation Mitigate Statin-Associated Muscle Symptoms? Pharmacological and Methodological Considerations"],"prefix":"10.1007","volume":"18","author":[{"given":"Beth A.","family":"Taylor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,10,12]]},"reference":[{"key":"251_CR1","unstructured":"Prescription cholesterol-lowering drug use in adults. https:\/\/www.cdc.gov\/nchs\/data\/databriefs\/db177.pdf . Accessed July 2017."},{"key":"251_CR2","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/S0140-6736(94)91755-8","volume":"344","author":"TR Pedersen","year":"1994","unstructured":"Pedersen TR, Kjekshus J, Berg K, Scandinavian Simvastatin Survival Study Group, et al. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383\u20139.","journal-title":"Lancet"},{"key":"251_CR3","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1001\/jama.279.20.1615","volume":"279","author":"JR Downs","year":"1998","unstructured":"Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS\/TexCAPS. Air Force\/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279:1615\u201322.","journal-title":"JAMA"},{"key":"251_CR4","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1056\/NEJMoa1315665","volume":"370","author":"MJ Pencina","year":"2014","unstructured":"Pencina MJ, Navar-Boggan AM, D\u2019Agostino RBS, Williams K, Neely B, Sniderman AD, et al. Application of new cholesterol guidelines to a population-based sample. N Engl J Med. 2014;370:1422\u201331.","journal-title":"N Engl J Med"},{"key":"251_CR5","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1592\/phco.30.6.541","volume":"30","author":"S Cham","year":"2010","unstructured":"Cham S, Evans MA, Denenberg JO, Golomb BA. Statin-associated muscle-related adverse effects: a case series of 354 patients. Pharmacotherapy. 2010;30:541\u201353.","journal-title":"Pharmacotherapy."},{"key":"251_CR6","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s11883-007-0050-3","volume":"9","author":"KA Sewright","year":"2007","unstructured":"Sewright KA, Clarkson PM, Thompson PD. Statin myopathy: incidence, risk factors, and pathophysiology. Curr Atheroscler Rep. 2007;9:389\u201396.","journal-title":"Curr Atheroscler Rep."},{"key":"251_CR7","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1161\/CIRCULATIONAHA.112.136101","volume":"127","author":"BA Parker","year":"2013","unstructured":"Parker BA, Capizzi JA, Grimaldi AS, Clarkson PM, Cole SM, Keadle J, et al. Effect of statins on skeletal muscle function. Circulation. 2013;127:96\u2013103.","journal-title":"Circulation"},{"key":"251_CR8","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10557-005-5686-z","volume":"19","author":"E Bruckert","year":"2005","unstructured":"Bruckert E, Hayem G, Dejager S, Yau C, Begaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients\u2013the PRIMO study. Cardiovasc Drugs Ther. 2005;19:403\u201314.","journal-title":"Cardiovasc Drugs Ther"},{"key":"251_CR9","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1097\/00041433-200212000-00007","volume":"13","author":"C Bolego","year":"2002","unstructured":"Bolego C, Baetta R, Bellosta S, Corsini A, Paoletti R. Safety considerations for statins. Curr Opin Lipidol. 2002;13:637\u201344.","journal-title":"Curr Opin Lipidol"},{"issue":"8","key":"251_CR10","first-page":"S58","volume":"2014","author":"Rosenson RS, Baker SK, Jacobson TA, Kopecky SL, Parker BA, The National Lipid Association\u2019s Muscle Safety Expert Panel. An assessment by the Statin Muscle Safety Task Force","year":"2014","unstructured":"Rosenson RS, Baker SK, Jacobson TA, Kopecky SL, Parker BA, The National Lipid Association\u2019s Muscle Safety Expert Panel. An assessment by the Statin Muscle Safety Task Force. update. J Clin Lipidol. 2014;2014(8):S58\u201371.","journal-title":"J Clin Lipidol."},{"key":"251_CR11","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1016\/j.amjcard.2011.01.052","volume":"107","author":"DG Pittman","year":"2011","unstructured":"Pittman DG, Chen W, Bowlin SJ, Foody JM. Adherence to statins, subsequent healthcare costs, and cardiovascular hospitalizations. Am J Cardiol. 2011;107:1662\u20136.","journal-title":"Am J Cardiol"},{"key":"251_CR12","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1002\/pds.3787","volume":"24","author":"JM Franklin","year":"2015","unstructured":"Franklin JM, Krumme AA, Tong AY, Shrank WH, Matlin OS, Brennan TA, et al. Association between trajectories of statin adherence and subsequent cardiovascular events. Pharmacoepidemiol Drug Saf. 2015;24:1105\u201313.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"251_CR13","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.jacc.2016.12.036","volume":"69","author":"MC Serban","year":"2017","unstructured":"Serban MC, Colantonio LD, Manthripragada AD, Monda KL, Bittner VA, Banach M, et al. Statin intolerance and risk of coronary heart events and all-cause mortality following myocardial infarction. J Am Coll Cardiol. 2017;69:1386\u201395.","journal-title":"J Am Coll Cardiol"},{"key":"251_CR14","doi-asserted-by":"crossref","first-page":"221","DOI":"10.7326\/M16-0838","volume":"167","author":"H Zhang","year":"2017","unstructured":"Zhang H, Plutzky J, Shubina M, Turchin A. Continued Statin prescriptions after adverse reactions and patient outcomes: a cohort study. Ann Intern Med. 2017;167:221\u20137.","journal-title":"Ann Intern Med"},{"key":"251_CR15","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jacl.2016.10.003","volume":"11","author":"JH Graham","year":"2017","unstructured":"Graham JH, Sanchez RJ, Saseen JJ, Mallya UG, Panaccio MP, Evans MA. Clinical and economic consequences of statin intolerance in the United States: results from an integrated health system. J Clin Lipidol. 2017;11:70\u20139.","journal-title":"J Clin Lipidol."},{"key":"251_CR16","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.jacl.2013.03.001","volume":"7","author":"MY Wei","year":"2013","unstructured":"Wei MY, Ito MK, Cohen JD, Brinton EA, Jacobson TA. Predictors of statin adherence, switching, and discontinuation in the USAGE survey: understanding the use of statins in America and gaps in patient education. J Clin Lipidol. 2013;7:472\u201383.","journal-title":"J Clin Lipidol."},{"key":"251_CR17","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/MOL.0000000000000174","volume":"26","author":"BA Taylor","year":"2015","unstructured":"Taylor BA, Thompson PD. Muscle-related side-effects of statins: from mechanisms to evidence-based solutions. Curr Opin Lipidol. 2015;26:221\u20137.","journal-title":"Curr Opin Lipidol"},{"issue":"111","key":"251_CR18","first-page":"1477","volume":"2011","author":"J Bouitbir","year":"1985","unstructured":"Bouitbir J, Charles AL, Rasseneur L, Dufour S, Piquard F, Geny B, et al. Atorvastatin treatment reduces exercise capacities in rats: involvement of mitochondrial impairments and oxidative stress. J Appl Physiol. 1985;2011(111):1477\u201383.","journal-title":"J Appl Physiol"},{"key":"251_CR19","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1089\/ars.2014.6190","volume":"24","author":"J Bouitbir","year":"2016","unstructured":"Bouitbir J, Singh F, Charles AL, Schlagowski AI, Bonifacio A, Echaniz-Laguna A, et al. Statins trigger mitochondrial reactive oxygen species-induced apoptosis in glycolytic skeletal muscle. Antioxid Redox Signal. 2016;24:84\u201398.","journal-title":"Antioxid Redox Signal"},{"key":"251_CR20","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1113\/jphysiol.2014.285577","volume":"593","author":"JE Mallinson","year":"2015","unstructured":"Mallinson JE, Marimuthu K, Murton A, Selby A, Smith K, Constantin-Teodosiu D, et al. Statin myalgia is not associated with reduced muscle strength, mass or protein turnover in older male volunteers, but is allied with a slowing of time to peak power output, insulin resistance and differential muscle mRNA expression. J Physiol. 2015;593:1239\u201357.","journal-title":"J Physiol"},{"key":"251_CR21","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/mus.22081","volume":"44","author":"MJ Hubal","year":"2011","unstructured":"Hubal MJ, Reich KA, De Biase A, Bilbie C, Clarkson PM, Hoffman EP, et al. Transcriptional deficits in oxidative phosphorylation with statin myopathy. Muscle Nerve. 2011;44:393\u2013401.","journal-title":"Muscle Nerve"},{"key":"251_CR22","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.jacc.2013.02.074","volume":"62","author":"CR Mikus","year":"2013","unstructured":"Mikus CR, Boyle LJ, Borengasser SJ, Oberlin DJ, Naples SP, Fletcher J, et al. Simvastatin impairs exercise training adaptations. J Am Coll Cardiol. 2013;62:709\u201314.","journal-title":"J Am Coll Cardiol"},{"key":"251_CR23","doi-asserted-by":"crossref","first-page":"e0168065","DOI":"10.1371\/journal.pone.0168065","volume":"11","author":"HR Chung","year":"2016","unstructured":"Chung HR, Vakil M, Munroe M, Parikh A, Meador BM, Wu PT, et al. The impact of exercise on statin-associated skeletal muscle myopathy. PLoS One. 2016;11:e0168065.","journal-title":"PLoS One"},{"key":"251_CR24","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.mayocp.2014.08.021","volume":"90","author":"M Banach","year":"2015","unstructured":"Banach M, Serban C, Sahebkar A, Ursoniu S, Rysz J, Muntner P, et al. Effects of coenzyme Q10 on statin-induced myopathy: a meta-analysis of randomized controlled trials. Mayo Clin Proc. 2015;90:24\u201334.","journal-title":"Mayo Clin Proc"},{"key":"251_CR25","first-page":"429","volume":"15","author":"RE Deichmann","year":"2015","unstructured":"Deichmann RE, Lavie CJ, Asher T, DiNicolantonio JJ, O\u2019Keefe JH, Thompson PD. The interaction between statins and exercise: mechanisms and strategies to counter the musculoskeletal side effects of this combination therapy. Ochsner J. 2015;15:429\u201337.","journal-title":"Ochsner J."},{"key":"251_CR26","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.jacc.2007.02.049","volume":"49","author":"L Marcoff","year":"2007","unstructured":"Marcoff L, Thompson PD. The role of coenzyme Q10 in statin-associated myopathy: a systematic review. J Am Coll Cardiol. 2007;49:2231\u20137.","journal-title":"J Am Coll Cardiol"},{"key":"251_CR27","first-page":"71","volume":"29","author":"SL Molyneux","year":"2008","unstructured":"Molyneux SL, Young JM, Florkowski CM, Lever M, George PM. Coenzyme Q10: is there a clinical role and a case for measurement? Clin Biochem Rev. 2008;29:71\u201382.","journal-title":"Clin Biochem Rev."},{"key":"251_CR28","doi-asserted-by":"crossref","first-page":"466","DOI":"10.4103\/0975-7406.84471","volume":"3","author":"R Saini","year":"2011","unstructured":"Saini R. Coenzyme Q10: the essential nutrient. J Pharm Bioallied Sci. 2011;3:466\u20137.","journal-title":"J Pharm Bioallied Sci."},{"key":"251_CR29","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.phrs.2015.07.008","volume":"99","author":"M Banach","year":"2015","unstructured":"Banach M, Serban C, Ursoniu S, Rysz J, Muntner P, Toth PP, et al. Statin therapy and plasma coenzyme Q10 concentrations\u2013a systematic review and meta-analysis of placebo-controlled trials. Pharmacol Res. 2015;99:329\u201336.","journal-title":"Pharmacol Res"},{"key":"251_CR30","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.clpt.2005.03.006","volume":"78","author":"H Paiva","year":"2005","unstructured":"Paiva H, Thelen KM, Van Coster R, Smet J, De Paepe B, Mattila KM, et al. High-dose statins and skeletal muscle metabolism in humans: a randomized, controlled trial. Clin Pharmacol Ther. 2005;78:60\u20138.","journal-title":"Clin Pharmacol Ther"},{"key":"251_CR31","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jacc.2012.09.036","volume":"61","author":"S Larsen","year":"2013","unstructured":"Larsen S, Stride N, Hey-Mogensen M, Hansen CN, Bang LE, Bundgaard H, et al. Simvastatin effects on skeletal muscle: relation to decreased mitochondrial function and glucose intolerance. J Am Coll Cardiol. 2013;61:44\u201353.","journal-title":"J Am Coll Cardiol"},{"key":"251_CR32","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s00228-017-2224-4","volume":"73","author":"M Asping","year":"2017","unstructured":"Asping M, Stride N, Sogaard D, Dohlmann TL, Helge JW, Dela F, et al. The effects of 2\u00a0weeks of statin treatment on mitochondrial respiratory capacity in middle-aged males: the LIFESTAT study. Eur J Clin Pharmacol. 2017;73:679\u201387.","journal-title":"Eur J Clin Pharmacol"},{"key":"251_CR33","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/j.amjcard.2006.12.063","volume":"99","author":"G Caso","year":"2007","unstructured":"Caso G, Kelly P, McNurlan MA, Lawson WE. Effect of coenzyme q10 on myopathic symptoms in patients treated with statins. Am J Cardiol. 2007;99:1409\u201312.","journal-title":"Am J Cardiol"},{"key":"251_CR34","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1016\/j.amjcard.2007.06.030","volume":"100","author":"JM Young","year":"2007","unstructured":"Young JM, Florkowski CM, Molyneux SL, McEwan RG, Frampton CM, George PM, et al. Effect of coenzyme Q(10) supplementation on simvastatin-induced myalgia. Am J Cardiol. 2007;100:1400\u20133.","journal-title":"Am J Cardiol"},{"key":"251_CR35","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.amjcard.2012.04.026","volume":"110","author":"DA Bookstaver","year":"2012","unstructured":"Bookstaver DA, Burkhalter NA, Hatzigeorgiou C. Effect of coenzyme Q10 supplementation on statin-induced myalgias. Am J Cardiol. 2012;110:526\u20139.","journal-title":"Am J Cardiol"},{"key":"251_CR36","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3109\/14017431.2012.756119","volume":"47","author":"MP Bogsrud","year":"2013","unstructured":"Bogsrud MP, Langslet G, Ose L, Arnesen KE, Sm Stuen MC, Malt UF, et al. No effect of combined coenzyme Q10 and selenium supplementation on atorvastatin-induced myopathy. Scand Cardiovasc J. 2013;47:80\u20137.","journal-title":"Scand Cardiovasc J."},{"key":"251_CR37","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1139\/cjpp-2012-0118","volume":"91","author":"J Fedacko","year":"2013","unstructured":"Fedacko J, Pella D, Fedackova P, Hanninen O, Tuomainen P, Jarcuska P, et al. Coenzyme Q(10) and selenium in statin-associated myopathy treatment. Can J Physiol Pharmacol. 2013;91:165\u201370.","journal-title":"Can J Physiol Pharmacol"},{"key":"251_CR38","doi-asserted-by":"crossref","first-page":"88","DOI":"10.3810\/psm.2012.11.1991","volume":"40","author":"RE Deichmann","year":"2012","unstructured":"Deichmann RE, Lavie CJ, Dornelles AC. Impact of coenzyme Q-10 on parameters of cardiorespiratory fitness and muscle performance in older athletes taking statins. Phys Sportsmed. 2012;40:88\u201395.","journal-title":"Phys Sportsmed."},{"key":"251_CR39","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.12659\/MSM.890777","volume":"20","author":"A Skarlovnik","year":"2014","unstructured":"Skarlovnik A, Janic M, Lunder M, Turk M, Sabovic M. Coenzyme Q10 supplementation decreases statin-related mild-to-moderate muscle symptoms: a randomized clinical study. Med Sci Monit. 2014;20:2183\u20138.","journal-title":"Med Sci Monit"},{"key":"251_CR40","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.atherosclerosis.2014.12.016","volume":"238","author":"BA Taylor","year":"2015","unstructured":"Taylor BA, Lorson L, White CM, Thompson PD. A randomized trial of coenzyme Q10 in patients with confirmed statin myopathy. Atherosclerosis. 2015;238:329\u201335.","journal-title":"Atherosclerosis."},{"key":"251_CR41","first-page":"e212","volume":"2","author":"C Buettner","year":"2016","unstructured":"Buettner C, Greenman RL, Ngo LH, Wu JS. Effects of coenzyme Q10 on skeletal muscle oxidative metabolism in statin users assessed using 31P magnetic resonance spectroscopy: a randomized controlled study. J Nat Sci. 2016;2:e212.","journal-title":"J Nat Sci."},{"key":"251_CR42","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1515\/jbcpp-2016-0149","volume":"28","author":"S Toth","year":"2017","unstructured":"Toth S, Sajty M, Pekarova T, Mughees A, Stefanic P, Katz M, et al. Addition of omega-3 fatty acid and coenzyme Q10 to statin therapy in patients with combined dyslipidemia. J Basic Clin Physiol Pharmacol. 2017;28:327\u201336.","journal-title":"J Basic Clin Physiol Pharmacol"},{"key":"251_CR43","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1016\/j.cjca.2016.01.003","volume":"32","author":"GB Mancini","year":"2016","unstructured":"Mancini GB, Baker S, Bergeron J, Fitchett D, Frohlich J, Genest J, et al. Diagnosis, prevention, and management of statin adverse effects and intolerance: canadian Consensus Working Group update (2016). Can J Cardiol. 2016;32:S35\u201365.","journal-title":"Can J Cardiol"},{"key":"251_CR44","first-page":"1","volume":"79","author":"TC Clarke","year":"2015","unstructured":"Clarke TC, Black LI, Stussman BJ, Barnes PM, Nahin RL. Trends in the use of complementary health approaches among adults: United States, 2002-2012. Natl Health Stat Report. 2015;79:1\u201316.","journal-title":"Natl Health Stat Report."},{"key":"251_CR45","unstructured":"Coenzyme Q10 market size to reach $1bn by 2024, to witness gain above 10% CAGR: Global Market Insights Inc. https:\/\/globenewswire.com\/news-release\/2016\/09\/01\/868768\/0\/en\/Coenzyme-Q10-Market-size-to-reach-1bn-by-2024-to-witness-gain-above-10-CAGR-Global-Market-Insights-Inc.html . Accessed July 2017."},{"key":"251_CR46","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1001\/jama.2016.3608","volume":"315","author":"SE Nissen","year":"2016","unstructured":"Nissen SE, Stroes E, Dent-Acosta RE, Rosenson RS, Lehman SJ, Sattar N, et al. Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3 randomized clinical trial. JAMA. 2016;315:1580\u201390.","journal-title":"JAMA"},{"key":"251_CR47","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ahj.2014.03.019","volume":"168","author":"HV Ganga","year":"2014","unstructured":"Ganga HV, Slim HB, Thompson PD. A systematic review of statin-induced muscle problems in clinical trials. Am Heart J. 2014;168:6\u201315.","journal-title":"Am Heart J"},{"key":"251_CR48","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.jacl.2016.05.002","volume":"10","author":"JA Tobert","year":"2016","unstructured":"Tobert JA, Newman CB. The nocebo effect in the context of statin intolerance. J Clin Lipidol. 2016;10:739\u201347.","journal-title":"J Clin Lipidol."},{"key":"251_CR49","doi-asserted-by":"crossref","first-page":"e547","DOI":"10.1097\/01.hjh.0000501498.29676.64","volume":"34","author":"P Sever","year":"2016","unstructured":"Sever P, Gupta A, Thompson D, Whitehouse A, Collier T, Dahlof B, et al. Lbos 01-04 the true incidence of statin-related adverse events in hypertensive patients revealed by comparison of blinded and un-blinded use of statin in the Anglo-Scandinavian Cardiac Outcomes Trial (Ascot). J Hypertens. 2016;34:e547\u20138.","journal-title":"J Hypertens"},{"key":"251_CR50","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s10557-017-6723-4","volume":"31","author":"RS Rosenson","year":"2017","unstructured":"Rosenson RS, Miller K, Bayliss M, Sanchez RJ, Baccara-Dinet MT, Chibedi-De-Roche D, et al. The Statin-Associated Muscle Symptom Clinical Index (SAMS-CI): revision for clinical use, content validation, and inter-rater reliability. Cardiovasc Drugs Ther. 2017;31:179\u201386.","journal-title":"Cardiovasc Drugs Ther"},{"key":"251_CR51","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1016\/j.jacc.2017.07.767","volume":"70","author":"BA Taylor","year":"2017","unstructured":"Taylor BA, Sanchez RJ, Jacobson TA, Chibedi-De-Roche D, Manvelian G, Baccara-Dinet MT, et al. Application of the\u00a0Statin-Associated Muscle Symptoms-Clinical Index to a randomized trial on statin myopathy. JACC. 2017;70:1680\u20131.","journal-title":"JACC."},{"key":"251_CR52","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.expneurol.2004.05.003","volume":"188","author":"CW Shults","year":"2004","unstructured":"Shults CW, Flint Beal M, Song D, Fontaine D. Pilot trial of high dosages of coenzyme Q10 in patients with Parkinson\u2019s disease. Exp Neurol. 2004;188:491\u20134.","journal-title":"Exp Neurol"},{"key":"251_CR53","doi-asserted-by":"crossref","first-page":"S78","DOI":"10.1016\/j.mito.2007.03.003","volume":"7","author":"HN Bhagavan","year":"2007","unstructured":"Bhagavan HN, Chopra RK. Plasma coenzyme Q10 response to oral ingestion of coenzyme Q10 formulations. Mitochondrion. 2007;7:S78\u201388.","journal-title":"Mitochondrion"},{"key":"251_CR54","doi-asserted-by":"crossref","first-page":"198","DOI":"10.3177\/jnsv.53.198","volume":"53","author":"K Nuku","year":"2007","unstructured":"Nuku K, Matsuoka Y, Yamagishi T, Miyawaki H, Sato K. Safety assessment of PureSorb-Q40 in healthy subjects and serum coenzyme Q10 level in excessive dosing. J Nutr Sci Vitaminol (Tokyo). 2007;53:198\u2013206.","journal-title":"J Nutr Sci Vitaminol (Tokyo)."},{"key":"251_CR55","first-page":"76","volume":"13","author":"M Kon","year":"2007","unstructured":"Kon M, Kimura F, Akimoto T, Tanabe K, Murase Y, Ikemune S, et al. Effect of coenzyme Q10 supplementation on exercise-induced muscular injury of rats. Exerc Immunol Rev. 2007;13:76\u201388.","journal-title":"Exerc Immunol Rev."},{"key":"251_CR56","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.1093\/jn\/133.10.3175","volume":"133","author":"S Kamzalov","year":"2003","unstructured":"Kamzalov S, Sumien N, Forster MJ, Sohal RS. Coenzyme Q intake elevates the mitochondrial and tissue levels of coenzyme Q and alpha-tocopherol in young mice. J Nutr. 2003;133:3175\u201380.","journal-title":"J Nutr"},{"key":"251_CR57","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1093\/toxsci\/kfi305","volume":"88","author":"JL Seachrist","year":"2005","unstructured":"Seachrist JL, Loi CM, Evans MG, Criswell KA, Rothwell CE. Roles of exercise and pharmacokinetics in cerivastatin-induced skeletal muscle toxicity. Toxicol Sci. 2005;88:551\u201361.","journal-title":"Toxicol Sci"},{"issue":"2","key":"251_CR58","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1080\/01926230590908213","volume":"33","author":"FR Westwood","year":"2005","unstructured":"Westwood FR, Bigley A, Randall K, Marsden AM, Scott RC. Statin-induced muscle necrosis in the rat: distribution, development, and fibre selectivity. Toxicol Pathol. 2005;33(2):246\u201357.","journal-title":"Toxicol Pathol"},{"key":"251_CR59","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1186\/s12891-016-1306-2","volume":"17","author":"AB Piette","year":"2016","unstructured":"Piette AB, Dufresne SS, Frenette J. A short-term statin treatment changes the contractile properties of fast-twitch skeletal muscles. BMC Musculoskelet Disord. 2016;17:449.","journal-title":"BMC Musculoskelet Disord."},{"key":"251_CR60","doi-asserted-by":"crossref","first-page":"445","DOI":"10.2131\/jts.36.445","volume":"36","author":"H Obayashi","year":"2011","unstructured":"Obayashi H, Nezu Y, Yokota H, Kiyosawa N, Mori K, Maeda N, et al. Cerivastatin induces type-I fiber-, not type-II fiber-, predominant muscular toxicity in the young male F344 rats. J Toxicol Sci. 2011;36:445\u201352.","journal-title":"J Toxicol Sci"},{"key":"251_CR61","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/j.1365-2125.2003.02044.x","volume":"57","author":"H Sinzinger","year":"2004","unstructured":"Sinzinger H, O\u2019Grady J. Professional athletes suffering from familial hypercholesterolaemia rarely tolerate statin treatment because of muscular problems. Br J Clin Pharmacol. 2004;57:525\u20138.","journal-title":"Br J Clin Pharmacol"},{"key":"251_CR62","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.amjcard.2011.08.045","volume":"109","author":"BA Parker","year":"2012","unstructured":"Parker BA, Augeri AL, Capizzi JA, Ballard KD, Troyanos C, Baggish AL, et al. Effect of statins on creatine kinase levels before and after a marathon run. Am J Cardiol. 2012;109:282\u20137.","journal-title":"Am J Cardiol"},{"key":"251_CR63","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1016\/S0026-0495(97)90218-3","volume":"46","author":"PD Thompson","year":"1997","unstructured":"Thompson PD, Zmuda JM, Domalik LJ, Zimet RJ, Staggers J, Guyton JR. Lovastatin increases exercise-induced skeletal muscle injury. Metabolism. 1997;46:1206\u201310.","journal-title":"Metabolism."},{"issue":"113","key":"251_CR64","first-page":"479","volume":"2012","author":"A Muraki","year":"1985","unstructured":"Muraki A, Miyashita K, Mitsuishi M, Tamaki M, Tanaka K, Itoh H. Coenzyme Q10 reverses mitochondrial dysfunction in atorvastatin-treated mice and increases exercise endurance. J Appl Physiol. 1985;2012(113):479\u201386.","journal-title":"J Appl Physiol"},{"key":"251_CR65","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.tox.2016.06.015","volume":"359\u2013360","author":"SO El-Ganainy","year":"2016","unstructured":"El-Ganainy SO, El-Mallah A, Abdallah D, Khattab MM, Mohy El-Din MM, El-Khatib AS. Elucidation of the mechanism of atorvastatin-induced myopathy in a rat model. Toxicology. 2016;359\u2013360:29\u201338.","journal-title":"Toxicology"},{"key":"251_CR66","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1186\/1550-2783-5-8","volume":"5","author":"M Cooke","year":"2008","unstructured":"Cooke M, Iosia M, Buford T, Shelmadine B, Hudson G, Kerksick C, et al. Effects of acute and 14-day coenzyme Q10 supplementation on exercise performance in both trained and untrained individuals. J Int Soc Sports Nutr. 2008;5:2783\u20138.","journal-title":"J Int Soc Sports Nutr"},{"key":"251_CR67","first-page":"337","volume":"45","author":"S Zhou","year":"2005","unstructured":"Zhou S, Zhang Y, Davie A, Marshall-Gradisnik S, Hu H, Wang J, et al. Muscle and plasma coenzyme Q10 concentration, aerobic power and exercise economy of healthy men in response to four weeks of supplementation. J Sports Med Phys Fitness. 2005;45:337\u201346.","journal-title":"J Sports Med Phys Fitness"},{"key":"251_CR68","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.atherosclerosis.2014.11.012","volume":"238","author":"TY Morioka","year":"2015","unstructured":"Morioka TY, Lee AJ, Bertisch S, Buettner C. Vitamin D status modifies the association between statin use and musculoskeletal pain: a population based study. Atherosclerosis. 2015;238:77\u201382.","journal-title":"Atherosclerosis."},{"key":"251_CR69","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.atherosclerosis.2016.11.011","volume":"256","author":"B Taylor","year":"2017","unstructured":"Taylor B, Lorson L, White M, Thompson PD. Low vitamin D does not predict statin-associated muscle symptoms but is associated with transient increases in muscle damage and pain. Atherosclerosis. 2017;256:100\u20134.","journal-title":"Atherosclerosis"},{"key":"251_CR70","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ijcard.2014.10.118","volume":"178","author":"M Michalska-Kasiczak","year":"2015","unstructured":"Michalska-Kasiczak M, Sahebkar A, Mikhailidis DP, Rysz J, Muntner P, Toth PP, et al. Analysis of vitamin D levels in patients with and without statin-associated myalgia - a systematic review and meta-analysis of 7 studies with 2420 patients. Int J Cardiol. 2015;178:111\u20136.","journal-title":"Int J Cardiol"},{"key":"251_CR71","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.cmet.2015.08.002","volume":"22","author":"TJ Schirris","year":"2015","unstructured":"Schirris TJ, Renkema GH, Ritschel T, Voermans NC, Bilos A, van Engelen BG, et al. Statin-induced myopathy is associated with mitochondrial complex III inhibition. Cell Metab. 2015;22:399\u2013407.","journal-title":"Cell Metab"}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40256-017-0251-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-017-0251-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-017-0251-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,19]],"date-time":"2020-10-19T17:22:33Z","timestamp":1603128153000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40256-017-0251-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,12]]},"references-count":71,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["251"],"URL":"https:\/\/doi.org\/10.1007\/s40256-017-0251-2","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,12]]}}}